Artal Group S.A. acquired a new stake in Tocagen Inc (NASDAQ:TOCA) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 100,000 shares of the company’s stock, valued at approximately $1,025,000.
Several other hedge funds have also made changes to their positions in TOCA. BlackRock Inc. increased its position in shares of Tocagen by 36.4% during the 4th quarter. BlackRock Inc. now owns 1,069,152 shares of the company’s stock worth $10,960,000 after purchasing an additional 285,396 shares in the last quarter. FMR LLC acquired a new stake in shares of Tocagen during the 2nd quarter worth about $9,624,000. JPMorgan Chase & Co. increased its position in shares of Tocagen by 52.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 630,375 shares of the company’s stock worth $7,886,000 after purchasing an additional 218,100 shares in the last quarter. Vanguard Group Inc. acquired a new stake in shares of Tocagen during the 2nd quarter worth about $5,036,000. Finally, Pure Financial Advisors Inc. acquired a new stake in shares of Tocagen during the 4th quarter worth about $1,324,000. Institutional investors own 37.49% of the company’s stock.
TOCA has been the subject of a number of recent analyst reports. BidaskClub upgraded shares of Tocagen from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. Zacks Investment Research upgraded shares of Tocagen from a “sell” rating to a “hold” rating in a research report on Thursday, January 11th. Finally, ValuEngine upgraded shares of Tocagen from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. Tocagen currently has an average rating of “Hold” and an average target price of $23.67.
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
Want to see what other hedge funds are holding TOCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tocagen Inc (NASDAQ:TOCA).
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.